Abstract:Recently, we and others reported that aged-tau knockout mice exhibit behavioural deficits, arguing for a role of functional tau protein in brain health. We also showed that these mice exhibit iron-dependent neurodegeneration and clioquinol (CQ), a drug that binds to iron, prevented the development of symptoms in tau KO mice. However, prospective treatments for neurodegenerative disorders will need to confer benefit to symptomatic patients. Here, CQ was given to symptomatic 12-months old tau KO mice to test whether this treatment was effective. Tau knockout mice (tau KO) and background C57BL6/SV129 control mice (WT), at 12 months of age, were treated with CQ chow (30mg/kg body weight /day) for 5.5 months. We monitored the mice by pole test and rotarod every three weeks during treatment period, and terminated this study when the mice were 17-months of age. Y maze tests were performed before the mice being euthanized for biochemical studies. Tyrosine hydroxylase staining was used for stereological estimation of nigral neurons. Dopamine was measured by HPLC. Before treatment commenced, tau KO mice exhibited cognitive loss (y-maze) and parkinsonism (rotarod, pole test), as previously reported. Over the course of the study, CQ treatment reversed the motor and cognitive impairment as evidenced by improvement in the Pole test (P<0.001) and Rotarod test (P=0.008) and y-maze (P=0.038). Restoration of behavioral disability reflected preservation of neuroanatomical features including enlargement of cortical thickness (P=0.026) and striatal enlargement (P=0.001) and reduction of the lateral ventricular area (P<0.001) at the conclusion of the study. These benefits conferred by CQ treatment could be attributed to reduction in iron load in the brain since treatment with CQ for 5.5 months had decreased iron in the brain (P=0.003 for hippocampus, and P=0.007 for SN) but not liver. Copper and zinc levels were unaffected. Here we report that iron chelation by CQ rescued several neurodegenerative phenotypes of aged tau KO mice, further supporting our hypothesis that tau plays a crucial role in age-related diseases. Importantly, these benefits were conferred to mice that began treatment after symptom manifestation, highlighting the potential for iron chelation approaches as disease modifying therapeutics for neurodegenerative diseases.

Motor and Cognitive Deficits in Aged Tau Knockout Mice in Two Background Strains

O4‐08‐03: Loss of Tau Induces Age‐dependent Neurodegeneration

Loss of Tau Induces Age-Dependent Anaemia with Reduced Longevity in Mice

Behavioral and neuropathological characterization over the adult lifespan of the human tau knock-in mouse

Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology

Behavioral and Neuropathological Phenotyping of the Tau58/2 and Tau58/4 Transgenic Mouse Models for FTDP-17

Rescue of Behavioral and neurodegenerative phenotypes in symptomatic tau KO mice: Therapeutic implications for neurodegenerative diseases

Sexual dimorphism in behavior, neuropathology, and biomarkers in a tau P301S mouse model of Alzheimer’s disease

Effects of age and dietary methionine restriction on cognitive and behavioural phenotypes in the rTg4510 model of frontotemporal dementia

The behavioural and neuropathologic sexual dimorphism and absence of MIP-3α in tau P301S mouse model of Alzheimer's disease

Tau Deficiency Down-Regulated Transcription Factor Orthodenticle Homeobox 2 Expression in the Dopaminergic Neurons in Ventral Tegmental Area and Caused No Obvious Motor Deficits in Mice

Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse.

Modeling Alzheimer’s Disease in Mouse without Mutant Protein Overexpression: Cooperative and Independent Effects of Aβ and Tau

Age-Related Neuropsychiatric Symptoms in Presenilins Conditional Double Knockout Mice

The Behavioural And Neuropathologic Sexual Dimorphism And Absence Of Mip-3 Alpha In Tau P301s Mouse Model Of Alzheimer'S Disease

Behavioral dysregulation and monoaminergic deficits precede memory impairments in human tau-overexpressing (htau) mice

Longitudinal changes in EEG power, sleep cycles and behaviour in a tau model of neurodegeneration

Age-progressing cognitive impairments and neuropathology in transgenic CRND8 mice

Humanized APOE genotypes influence lifespan independently of tau aggregation in the P301S mouse model of tauopathy

Humanized Tau Mice with Regionalized Amyloid Exhibit Behavioral Deficits but No Pathological Interaction

A systematic review and meta-analysis of tau phosphorylation in mouse models of familial Alzheimer's disease